We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Hematology-Oncology

Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma

MedXY Editorial Team•Sep 22, 2026•Hematology-Oncology
maintenance therapysurvival outcomesmultiple myeloma自家造血幹細胞移植

Highlight

1. Maintenance therapy after autologous hematopoietic cell transplantation (AHCT) significantly improves 3-year overall survival in newly diagnosed multiple myeloma (NDMM) patients compared to no maintenance.

2. Lenalidomide maintenance demonstrates the highest survival benefit (86% OS at 3 years), followed by bortezomib (83%) and thalidomide (80%).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Contemporary Surgical Management of Vulvar Cancer: Balancing Improved Survival with Increased Reoperation Rates — Insights from a Finnish Nationwide StudyThis review synthesizes evidence that modern personalized surgical strategies for vulvar squamous cell carcinoma enhance survival outcomes despite higher reoperation rates, emphasizing evolving surgical techniques, sentinel lymph node biopsSep 27, 2026Soluble BCMA as a Key Biomarker Defining Tumor Phenotypes and Prognosis in Newly Diagnosed Multiple MyelomaSoluble BCMA levels in newly diagnosed multiple myeloma patients reveal distinct tumor phenotypes and predict prognosis more strongly than tumor volume, enabling improved risk stratification and clinical decision-making.Sep 27, 2026Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple MyelomaPKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.Sep 22, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Evaluating First-Line Chemotherapy Strategies in Anaplastic Thyroid Cancer: Insights from a German Multicenter Registry
A multicenter German registry study comparing carboplatin/paclitaxel to other chemotherapy regimens in anaplastic thyroid cancer found no survival advantage, highlighting the importance of molecular diagnostics and multimodal treatment appr
Sep 21, 2026
Immunotherapy in Head and Neck Squamous Cell Carcinoma with Low PD-L1 Expression: A Meta-Analytic Insight into Survival OutcomesA meta-analysis reveals immune checkpoint inhibitors may reduce survival in head and neck squamous cell carcinoma patients with PD-L1 combined positive scores less than 1, signaling caution in this subgroup’s treatment.Sep 21, 2026
Contemporary Outcomes of Autologous Stem Cell Transplantation in AL Amyloidosis: Insights from a Decade-Long Multicenter StudyA multicenter retrospective study of 1047 AL amyloidosis patients undergoing autologous stem cell transplantation (2010–2020) demonstrates improved safety, deep hematologic responses, and durable survival, affirming ASCT’s vital role in treSep 21, 2026